Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
Major study on DiagnoCure's GCC biomarker published in Jama
March 3rd, 2009
The Journal of the American Medical Association (JAMA), Vol. 301, #7, this week published positive results from a major prospective 5-year multicenter study of over 400 enrolled patients demonstrating that guanylyl cyclase C (GCC) is the strongest independent predictor of colorectal cancer recurrence in patients considered low risk by current assessment methods. The study was conducted by investigators from Thomas Jefferson University, with contributions from McGill University, the Fox Chase Cancer Center and others. DiagnoCure Inc. owns the exclusive worldwide diagnostic rights to the GCC biomarker, and since last September has offered the Previstage(TM) GCC test to physicians and...
Source: Cancer Weekly (2009-03-03)
|
